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Abstract
Poxvirus morphogenesis is a complex process that involves the successive wrapping of the virus in host cell membranes. We
screened by plaque assay a focused library of kinase inhibitors for those that caused a reduction in viral growth and
identified several compounds that selectively inhibit phosphatidylinositol 3-kinase (PI3K). Previous studies demonstrated
that PI3Ks mediate poxviral entry. Using growth curves and electron microscopy in conjunction with inhibitors, we show
that that PI3Ks additionally regulate morphogenesis at two distinct steps: immature to mature virion (IMV) transition, and
IMV envelopment to form intracellular enveloped virions (IEV). Cells derived from animals lacking the p85 regulatory subunit
of Type I PI3Ks (p85a2/2b2/2) presented phenotypes similar to those observed with PI3K inhibitors. In addition, VV appear
to redundantly use PI3Ks, as PI3K inhibitors further reduce plaque size and number in p85a2/2b2/2 cells. Together, these
data provide evidence for a novel regulatory mechanism for virion morphogenesis involving phosphatidylinositol dynamics
and may represent a new therapeutic target to contain poxviruses.
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plasma membrane or in endosomes [14,15,16]. After delivery of the
viral core to the cytoplasm, early viral gene transcription and
translation initiates replication and morphogenesis.
Morphogenesis is regulated at multiple steps [17], which have been
characterized by electron microscopy in conjunction with mutant
viruses containing deletions or temperature-sensitive alleles of viral
proteins. Morphogenesis ensues approximately four hours after entry
with the appearance of viral crescents [18,19], which consist of semispherical membranes containing viral proteins apposed to the
viroplasm. The crescent membrane extends to encase viroplasm,
forming a spherical immature virion (IV). The transition from IV to
IMV depends on several events, including proteolysis of core proteins
such as A3 (P4b), A10 (P4a), and L4 (P25K), and formation of
disulfide bonds within nascent viral proteins L1 and E10
[20,21,22,23]. IMV formation also depends on the viral kinase F10
[24], core proteins P4a, A10, P4b, A3, P25, and L4 [25], and on
redox proteins G4 and E10 [26,27,28,29]. Mutations in these
proteins result in slightly different phenotypic defects, including an
inability to form complete crescents, misincorporation of the
viroplasm with or without crescent resolution, malformed cores, or
incomplete virion maturation.
Once formed, a subset of IMVs traffic along microtubules to a
juxta-nuclear region where they are enveloped in host-cell membranes derived from endosomes or from the Golgi apparatus to form

Introduction
Orthopoxviruses, including vaccinia virus (VV), monkeypox
(MPX), and variola (VarV), are large dsDNA viruses that cause
characteristic umbilicated vesiculo-pustular skin lesions (‘‘pox’’).
VarV is the causative agent of smallpox, and VV is used for
vaccination against smallpox. Although smallpox has been
eradicated, naturally occurring poxviruses are still of concern to
humans. Molluscum contagiosum is prevalent in children and
immunocompromised individuals [1,2], while MPX is endemic in
Africa and has the potential for dissemination as evidenced by the
2003 outbreak in the United States [3,4].
Infection is initiated upon entry of either of two forms of the virus.
The first, called the Intracellular Mature Virus (‘‘IMV’’, and also
called Mature Virion ‘‘MV’’), consists of a brick-shaped viral core
surrounded by one or two lipid bilayers derived from an ER-golgi
intermediate compartment (ERGIC) [5,6,7,8]. IMV enter the cell
either through direct fusion with the plasma membrane or by
internalization and fusion with an endocytic compartment
[9,10,11,12]. A second infectious form of the virus, called the
extracellular enveloped virus (‘‘EEV’’, and also called Enveloped
Virus ‘‘EV’’) [13], is released from the cell surface and consists of an
IMV enveloped in additional host-cell derived membranes. Entry of
EEV requires disruption of the outer viral membrane either at the
PLoS ONE | www.plosone.org
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IEV (Intracellular Enveloped Virions) [30,31,32,33,34]. The mechanisms controlling envelopment are less well understood, but
evidence suggests the involvement of F12 and A36, F13, A33, A34,
A56 and B5 [13], which physically associate or facilitate localization
of other proteins. For example, F13 and A34 have been shown to
regulate the cellular trafficking of B5 and its incorporation into the
IEV [35,36]. Ultimately, the interaction of these proteins allows the
virus to utilize host membranes for envelopment.
While much information is available about the viral proteins
that govern entry and maturation, much less is known about the
host cell factors that contribute to trafficking and membrane
wrapping processes. In this paper, we provide evidence that
maturation of several orthopoxviruses, including VV, MPX and
ectromelia, is regulated by host phosphatidylinositol-3 family
kinases (PI3K). PI3Ks catalyze addition of a phosphate group to
the D3 hydroxyl of the inositol ring of phosphatidylinositol
[37,38,39], and regulate many cellular processes including growth
factor and hormonal signaling, autophagy, nutrient sensing, and
endosomal trafficking [37,40,41,42].
PI3Ks are encoded by multiple genes and are categorized into
three classes based on domain structure and substrate preference
(reviewed by [38]). Kinases within each class are controlled by
regulatory proteins. These proteins are encoded by multiply
spliced genes, which can generate additional signaling complexity.
Genes encoding PI3Ks are frequently mutated in human cancers,
making this class of enzymes an important pharmaceutical target
[43,44,45,46].
Many viruses, including VV and Cowpox, activate PI3Ks to
inhibit cellular apoptosis [47,48,49]. Here we demonstrate that
poxviruses additionally utilize PI3K at several distinct stages of
morphogenesis, including early and late gene expression, late
protein trafficking and envelopment, and maturation of virions,
suggesting a much broader role for this class of host molecules than
has been previously recognized.

vaccinia virus were conducted at Emory University under BSL-2
conditions. 100PFU of vaccinia virus strain WR was diluted in
500 mL of 2% FBS/DMEM and added to monolayers of naı̈ve
BSC40, p85WT, p85a2/2, or p85a2/2b2/2 cells in 12 well
dishes. Virus was allowed to adsorb to and enter the cells for one
hour at 37uC in 5% CO2. After 1 hour, virus was removed and
monolayers were washed twice with 1 mL PBS. Media was then
replaced with 10% FBS/DMEM containing PI3K inhibitors at
different concentrations. Drugs were resuspended in 100%
DMSO, and DMSO controls were performed in conjunction
with assays using PI3K inhibitors. Two days after infection,
monolayers were fixed and stained with crystal violet solution
(0.1% crystal violet and 20% ethanol). The concentration of drug
needed to reduce plaque numbers by half (IC50) was calculated by
fitting the data to a linear regression model using Prism software
(GraphPad Prism Software, Inc., La Jolla, CA). Experiments with
ectromelia virus were performed at the Saint Louis University
School of Medicine. For these experiments, ECTV-Moscow strain
p4 was used to infect BSC-1 cells at 50–75 plaques/well of a 12well culture plate for one hour in DMEM (Lonza, Basel,
Switerland) supplemented with 2% Fetal Clone II (FCII, Hyclone,
Thermo Scientific, Pittsburgh, PA). Serial dilutions of the
compounds were made in DMEM-2% FCII and added to the
infected cells along with DMEM-5% FCII-1% carboxymethylcellulose (Sigma-Aldrich; St. Louis, MO). The cultures were
incubated 4–5 days and stained with crystal violet (0.13% crystal
violet, 5% ethanol, 10% formaldehyde) to visualize plaque
formation. IC50 values were calculated as described. Experiments
with monkeypox were performed at the Centers for Disease
Control and Prevention (CDC) in Atlanta, GA under BSL2+
conditions. For these experiments, 50PFU/mL of strain V79-1005 in 2% FBS RPMI (Gibco; Carlsbad, CA) was added to BSC40
cells for one hour at 35.5uC in a 6% CO2 incubator. After one
hour virus was removed and monolayers were washed twice with
2% RPMI media. Media was replaced with 2%RPMI/1%DMSO
containing PI3K inhibitors at different concentrations and cells
were incubated at 35.5uC in 6% CO2 for three days. After three
days, monolayers were fixed and stained with 2X CV. IC50 and
IC20 values were calculated as described.

Materials and Methods
Cells, viruses and plaque assays
BSC40 cells (ATCC) were grown in DMEM or RPMI (Cellgro,
MediaTech, Inc; Manassas, VA) supplemented with 10%FBS
(Atlanta Biologicals; Norcross, GA) and 10 IU/mL Penicillin and
10 mg/mL streptomycin (P/S; Cellgro, MediaTech, Inc.; Manassas,
VA). BHK cells were grown in alpha-MEM (Gibco; Carlsbad, CA)
supplemented with 10%FBS and P/S; p85WT and p85a2/2 cells
were grown in DMEM with 10%FBS and P/S, while p85a2/2b2/2
cells were grown in DMEM with 15%FBS and P/S. All cells were
grown at 37uC in a 5% CO2 incubator. p85-deficient cells were
provided by Lewis Cantley. Mouse embryonic fibroblasts were
isolated from embryos that were heterozygous or homozygous for
knockout of the PI3K-family related genes PIK3R1 and PIK3R2
[50,51]. Viral strains were grown and propagated as previously
described [52]. All strains were titered on BSC40 cells.

Western analysis
BHK or p85 cells were grown in 10 cm tissue culture dishes and
infected at an MOI of five with vaccinia virus strain Western
Reserve (WR). Briefly, virus was incubated in a minimal amount
of 2% FBS/DMEM for one hour at 37uC to allow virus to adsorb
and enter monolayers. Monolayers were washed once with PBS
and media was replaced with 10%FBS DMEM with or without
PI3K inhibitors for an additional sixteen hours. Western analysis
of P4b/4b was done in conjunction with infection periods of 6, 16
or 24 hours. Cells were lysed in RIPA buffer (Cell Signaling;
Beverly, MA). The amount of protein was quantified using the
Bio-Rad Dc Protein Assay Kit (Bio-Rad; Hercules, CA), and 50 mg
was separated by SDS-PAGE. For acid-bypass experiments
p85WT and p85-deficient cells were grown in 10 cm tissue
culture dishes and infected and analyzed by the same protocol as
Mercer and Townsley et al. [54,55]. Briefly, WR was added to cells
at an MOI of 5 in 2 mL of pre-cooled Opti-Pro SFM
supplemented with P/S and 20 mL 200 mM L-Glutamine (Gibco;
Carlsbad, CA) and virus was allowed to bind to cells at 4uC for one
hour. Cells were treated with pre-warmed PBS and 1 mM MES,
pH of 5 for five minutes at 37uC in 5% CO2. Media was then
removed and the monolayers washed once with 5 mL pre-warmed
10% FBS/DMEM, and media was replaced with 10% FBS/
DMEM. After 2 hours, the infection was stopped by rinsing the

PI3K Inhibitors
AS605240 and AS604850 were chemically synthesized as
described [53] and are referred to in the text as AS1 and AS2,
respectively. The PI3K-alpha Inhibitor 2 #B0304 or 3-(4Morpholinothieno[3,2-d]pyrimidin-2-yl)phenol, referred to as
B0304, was obtained from Echelon Biosciences, and LY294002
was obtained from Sigma-Aldrich (St. Louis, MO).

Plaque assays and calculation of IC50 Values
To calculate IC50 values, PI3K inhibitors were added post-viral
adsorption to poxviral-infected monolayers. Experiments with
PLoS ONE | www.plosone.org
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Thermo Scientific, Pittsburgh, PA). Compound dilutions were
mixed with BSC-1 cells at 5000 cells per reaction
in 100 ml total volume. At the specified time point, 20 ml of MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] solution (CellTiter 96 Aqueous One
Solution Cell Proliferation Assay, Promega; Madison, WI) was added
to each reaction and incubated 2–4 hours. The absorbance was
measured at 490 nm and used to determine percent cell viability for
each reaction compared to untreated cells. Compound concentration
was plotted versus percent cell viability to determine the concentration at which the cell viability was reduced by 50% (CC50).

cells with PBS and lysing the cells with RIPA Buffer (Cell
Signaling; Beverly, MA). Proteins were quantified as above. To
generate blots, proteins were then transferred to nitrocellulose, and
the membranes were blocked with 3% BSA in Tris-buffered saline
containing 0.5% Tween-20 (TBST) for one hour. Membranes
were probed with antibodies in the blocking solution for an
additional hour. For infections with B5-GFP [56] and F13-GFP
VV [57], membranes were probed with GFP antibody (1:1000,
Living Colors Full-length A.v. Polyclonal Antibody, Clonetech;
Mountain View, CA). Anti-L1 (10F5) was a gift from Jay Hooper
at USAMRIID and was used at 1:1000 dilution for western blots
and 1:50 for microscopy. Anti-P4b/4b was a gift from Bernard
Moss at NIH, and was used at 1:3500. Anti-E3 was a gift from
Stuart Isaacs at University of Pennsylvania and was used at
1:1000. Bands were detected using anti-Mouse or anti-Rabbit
HRP conjugated antibodies (GE Healthcare; UK) and blots were
developed using Pierce ECL Western Blotting Substrate (Thermo
Scientific; Waltham, MA). Independent experiments were performed in duplicate to confirm Western blot results. Fold change
was calculated from a representative experiment by quantifying
band intensity using Adobe Photoshop v10.0.1 and samples were
normalized against Tubulin controls. Data is expressed as the fold
change relative to untreated samples.

Trypan Blue Exclusion Assay
BHK cells were grown to ,80% confluency in 12-well tissue
culture dishes and treated with 50 mM AS1 or AS2 or treated with
0.5% DMSO in 10%FBS/DMEM. At each time point, cells were
trypsinized with 0.5 mL 0.25% Trypsin/EDTA (Cellgro, MediaTech, Inc.; Manassas, VA), and combined with removed
supernatant. Cells were spun down at 1500xg for five minutes.
A supernatant volume of 800 ml was removed and replaced with
0.4% (w/v) Trypan Blue in saline (Cellgro, MediaTech, Inc.;
Manassas, VA) and cells were resuspended. Viable (clear) and
nonviable (blue) cells were counted on a hemacytometer. Samples
were scored from duplicate tissue culture wells.

Microscopy

TUNEL Assay

Deconvolution microscopy was carried out as previously
described [52]. Spinning disk microscopy was performed at the
Heuser lab on a Zeiss Axioplan 2 with Yokagawa CSU 10
confocal scanner unit.

BHK or p85WT, p85a2/2 or p85a2/2b2/2 cells were grown to
near confluency on slides prepared for microscopy. Cells were treated
with 50 mM AS1 or AS2, and 20 mM LY294002 or B0304 in
10%FBS/DMEM for sixteen hours. Apoptosis was detected using the
ApoTag Fluorescein in situ Apoptosis Detection Kit (Chemicon
International, Millipore; Billerica, MA). As a positive control cells
were treated with 20U DNase1 (Epicentre; Madison, WI) for 10
minutes at room temperature post-fixation. Each experiment was
carried out with duplicate microscope slides. Two images were taken
per slide, and ,700 cells were counted per condition.

Growth Curves
BHK or p85WT, p85a2/2 or p85a2/2b2/2 cells were grown
to ,80% confluence in triplicate 12-well tissue culture dishes.
Prior to infection cell numbers were quantified, and cells were
infected at an MOI of 5, 1, 0.01, 0.001, or 0.0001 in 2%FBS/
DMEM for one hour at 37uC with vaccinia virus strain WR. After
adsorption, monolayers were washed twice with 1 mL PBS and
media was replaced with 10%FBS DMEM with or without PI3K
inhibitors. AS1 and AS2 were used at 50 mM, Rifampicin at
0.1 mg/mL, and the carrier DMSO was maintained at 0.5%. At
each time point, the supernatant was removed and the monolayers
were scraped into 0.5 mL 2%FBS/DMEM. Cell-associated virus
was isolated by freezing and thawing cells three times, and then
centrifuging at 500xg for three minutes to remove cell debris.
Supernatants containing released virus or cell-associated virus
were diluted in 2%FBS/DMEM and then added to naı̈ve
(uninfected) BSC40 monolayers.

Electron Microscopy
Electron microscopy was performed by the Heuser lab at
Washington University at St. Louis. Briefly, BHK, HeLa or
p85WT or p85a2/2b2/2 cells were grown on Thermanox dishes
(Nunc, Fisher Scientific), and infected with MVA or B5-GFP WR
virus as previously described [58,59]. After a 17-hour infection
period cells were fixed and processed for microscopy. For
glutaraldehye/KMnO4 fixation and staining, cultures were fixed
for 1 hour at room temperature with 2% glutaraldehyde in
NaHCa Buffer (30 mM HEPES, pH 7.4 with NaOH, 100 mM
NaCl, 2 mM CaCl, and 10 mM MgCl2), washed 2 times with
NaHCa buffer for 5 minutes, washed for 15 minutes with
quenching solution (50 mM glycine, 50 mM lysine, 50 mM
NH4Cl in NaHCa Buffer), followed by 56 washes with NaHCa
buffer (5 minutes each wash) and 2 washes of 0.1M NaCl (10
minutes each wash). Samples were stained with 0.5% KMnO4 in
0.1M NaCl, washed twice with 0.1M NaCl and dehydrated with
25%, 50%, 75%, 95% and 100% ethanol over 20 minutes.
Samples were embedded using the Protocol for Fast Embedding.
Coverslips were dipped sequentially in: 100% ethanol, 100%
ethanol, 100% propylene oxide, 100% propylene oxide, 50/50
(v/v) propylene oxide and epoxy resin, 50/50 (v/v) propylene
oxide and epoxy resin, 100% epoxy resin, 100% epoxy resin,
inverted over Beem capsules and allow to polymerize at 65uC. For
glutaraldehyde/OsO4 fixation and staining cultures were rinsed in
Ringer’s solution and fixed for 30–60 minutes at room
temperature in 2% glutaraldehyde in NaHCa buffer. Post-fixation

Comet Assays
BSC40 cells were allowed to form confluent monolayers in 6well dishes. Media was removed and replaced with 100PFU/well
IHD-J vaccinia virus diluted in 500 mL 2% FBS/DMEM. Virus
adsorbed to the cells for one hour at 37uC. After adsorption virus
was removed and monolayers were washed twice with 1 mL PBS,
and media was replaced with 10%FBS DMEM with or without
PI3K inhibitors. AS1 and AS2 were added at 50 mM, while B0304
and LY294002 were added at 20 mM final concentrations. DMSO
was added at a final concentration of 0.5%. Infections were
stopped after 48 hours with the addition of crystal violet stain.

MTS Assay
Serial dilutions of PI3K compounds were made in DMEM (Lonza;
Basel, Switerland) supplemented with 2% Fetal Clone II (Hyclone,
PLoS ONE | www.plosone.org
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Figure 1. PI3Ks regulate plaque morphology and early protein production. A. PI3K inhibitors reduce plaque size in BSC40 cells. Cells were
infected with 100 PFU of vaccinia virus (VV), strain WR. Inhibitors were added one hour post viral entry. First row: LY294002, 20 mM; B0304, 20 mM;
AS1, 50 mM; AS2, 50 mM (LY294002 and B0304 are in 0.2% DMSO and AS1 and AS2 are in 0.5% DMSO); 0.5% DMSO alone. Insets show representative
plaques from 50 mM AS1 and 0.5% DMSO treated wells. Second row: 10 mM Wortmannin in 0.1% DMSO did not appear to reduce VV plaque size; 0.1%
DMSO control. Results are from three independent trials. B. p85WT and p85a2/2 cells form two times more plaques than p85a2/2b2/2 cells. Cells
were infected with equal amounts of virus and monolayers were stained with crystal violet 48 hours post infection. Results are from eight
independent trials. C. PI3K inhibitors do not decrease early viral protein expression. BSC40 cells were infected at pH 7.4 and MOI = 5 with VV and PI3K
inhibitors were added 1 hour post-viral entry and allowed to infect for an additional 2 hours. Proteins were subjected to western analysis by anti-E3
mAb and anti-Tubulin mAb. For quantification (right) bands were normalized to tubulin loading control and data is expressed as the fold change
relative to DMSO-treated samples. D. Early protein expression is reduced in p85-deficient cells. Cells were infected at an MOI = 5 with VV at pH = 7.4
and analyzed as in C. E. Early protein expression is reduced in p85-deficient cells. Cells were infected at an MOI = 5 with VV. Virus was bound to cells
at 4uC, after which cells were moved to 37uC with PBS, pH = 5. Following a 2 hour infection, equal amounts of protein were subjected to western
analysis with anti-E3 mAb or anti-Tubulin, and quantitated as in C.
doi:10.1371/journal.pone.0010884.g001

cells were rinsed twice in NaHCa buffer and stained with TA (1%
tannic acid, 0.075% saponin in NaHCa Buffer) for 15 minutes at
room temperature. Cells were then rinsed twice with NaHCA
buffer, twice with 0.1M cacodylate buffer, pH 7.4, and postfixed
with 0.5% OsO4 in 0.1 M cacodylate buffer, pH 7.4 for 15
minutes at room temperature. After OsO4 samples were rinsed
twice in 0.1 M cacodylate buffer pH 7.4 (5 minutes each wash)
and twice in 0.1 M sodium acetate buffer, pH 5.2 (20 minutes
each wash). Samples were then stained with 4% uranyl acetate in
50 mM sodium acetate buffer for 15 minutes in the dark at room
temperature. Samples were then rinsed twice in 0.1 M sodium
acetate buffer (5 minutes each rinse) and dehydrated as above.
Samples were embedded in resin as described above. Samples
were prepped for EM as previously described [60].

to control-treated monolayers (Figure 1A). Wortmannin did not
decrease plaque size up to 48 hours after infection, the longest time
tested. However, this drug, in contrast to AS1, AS2 B0304 and
LY294002, is a covalent inhibitor that reacts with tissue culture
components and was not replenished during the experiment
[61,62,63,64,65]. IC50 values for AS1, AS2, B0304, and LY294002
were similar for several orthopoxviral species, including VV, MPX,
and ectromelia (Table 1). Lighter crystal violet staining was apparent
for MPX-infected monolayers. Therefore, IC20 values for orthopoxviral infected cells are presented in Table S1. Notably, fold differences
in IC50 and IC20 values were similar for the different orthopoxviruses.
To ensure that PI3K inhibitors were targeting a host and not a
viral kinase, we next assessed VV infection in fibroblast cells
derived from wild type animals or from animals with homozygous
deletions in p85a (85a2/2) or in both p85a and p85b (p85a2/2
b2/2), the regulatory subunits of the Type 1 PI3Ks. Because the
stability of the catalytic subunit depends on the regulatory subunit,
p85a2/2 and p85a2/2b2/2 cells are deficient in type 1 PI3K
activity [50,66]. In accordance with results with PI3K inhibitors,
the number of plaques appeared two-fold lower in the p85a2/2
b2/2 cells compared to wild type cells (Figure 1B).

Results
PI3Ks regulate plaque morphology
To identify host kinases utilized by VV, we screened a small
directed library, which included approximately 350 novel and
previously described inhibitors, for those that decreased the size of
plaques. Monolayers were treated with compounds at a final
concentration of 50–100 mM. The construction and composition
of the library is described elsewhere (S.M, D.K., and W.G.B. in
preparation), but consisted of compounds that inhibited tyrosine
kinases as well as other kinases. Here we focus on two inhibitors
present in the library called AS1 (AS605240) and AS2 (AS604850),
which decreased plaque size to pinpoints (Figure 1A).
AS1 and AS2 inhibit the p110-gamma subunit of the type 1 PI3K;
but they also inhibit the other PI3K subtypes at higher concentrations
(Table 1) [61]. To confirm that inhibition of PI3Ks by AS1 and AS2
could account for the pinpoint plaques, several well-characterized
PI3K inhibitors were tested including wortmannin and LY294002,
and a p110-alpha specific inhibitor B0304. Addition of LY294002
and B0304 after adsorption of the virus decreased plaque size relative

PI3K Regulation of early protein production
The PI3K inhibitor LY294002 can disrupt eIF4 complexes during
VV infection, and reduces both late proteins and virion production
[67]. We next determined the stage(s) viral morphogenesis is
disrupted in cells treated with the PI3K inhibitors AS1 and AS2
(one hour after adsorption), or in p85-deficient cells. No significant
difference in E3 levels, a measure of early protein synthesis, was
evident in cells treated with AS1 or AS2 compared to untreated cells
(Figure 1C). These data suggest that PI3Ks sensitive to AS1 or AS2
are not required for expression of early viral proteins, but exert their
effects at later stages of maturation. In contrast, E3 levels were
reduced by 62% and 93%, respectively, in the p85a2/2 and

Table 1. 50% Inhibitory Concentration (IC50) of PI3K inhibitors added post-adsorption to poxvirus-infected monolayers.

Inhibits:

Vaccinia IC50

Ectromelia IC50

Monkeypox IC50

Other Targets:

AS1

p110-gamma

37.461.1 mM

13.061.3 mM

12.163.9 mM

p110-alpha, p110-beta, p110-delta,
PKCbII1

AS2

p110-gamma

44.662.1 mM

44.7614.2 mM

9.364.3 mM

p110-alpha, p110-beta, p110-delta1

B0304

p110-alpha

9.860.3 mM

1.860 mM

6.164.8 mM

p110-beta, p110-delta, p110gamma2

LY294002

Broad-Spectrum PI3K Inhibitor3

44.166.9 mM

14.464.2 mM

20.3610.7 mM

1

[61].
[108].
[65].
doi:10.1371/journal.pone.0010884.t001
2
3
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p85a2/2b2/2 cells relative to the p85WT cells (Figure 1D). To
confirm that this difference was a result of reduced protein levels, and
not due to a defect in endocytic uptake in p85-deficient cells, we
adsorbed virus to cells at 4uC and reduced the pH to catalyze entry
[55]. Under these conditions, E3 levels were still reduced by 55% and
85%, respectively, in the p85a2/2 and p85a2/2b2/2 cells relative to
the p85WT cells (Figure 1E), suggesting that the observed reduction
in E3 levels in p85-deficient cells (Figure 1D) resulted from a defect in
early protein accumulation and not entry. We cannot rule out the

possibility that an early p85-dependent transport or transcription step
occurs before the addition of inhibitors. This may account for the
apparent differences in E3 levels between p85-deficient cells and the
inhibitors.

PI3Ks mediate late protein production
We next investigated the role of PI3Ks in the production of
IEV/EEV proteins using VV strains that express the B5 and F13
as GFP fusions under their own promoters (B5-GFP and F13-

Figure 2. PI3K inhibitors reduce late viral protein expression. BHK cells were infected with VV at an MOI of 5, and PI3K inhibitors were added
following entry. After 16 hours proteins were subjected to western analysis with various antibodies, including anti-Tubulin to ensure equal loading.
Quantitation (right) is described in Methods. Data are expressed as the fold change relative to DMSO-treated samples. A. Cells were infected with VV
strain WR expressing B5-GFP under its own promoter, and subjected to western analysis with GFP (top) or tubulin (bottom) antibodies. B. Cells were
infected with VV strain WR expressing F13-GFP, and analyzed as in A. C. Cells were infected with VV strain WR for 6 or 16 hours. Filters were probed
with P4b/4b or tubulin antibodies. Results are from two or three independent trials.
doi:10.1371/journal.pone.0010884.g002
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through different mechanisms: AS1 inhibits late protein production, whereas AS2 does not.
In accordance with the results with AS1, p85a2/2 and p85a2/2
b2/2 cells had reduced levels of F13, B5, and p4b and 4b (Figure 3A,
3B, 3C). In addition, the proteolysis of p4b into 4b does not appear to
be significantly inhibited in the p85a2/2 and p85a2/2b2/2 cells
(Figure 3C). Notably, the degree of reduction in late proteins
appeared correlated with the genetic deficiency of the cell type
used; thus, the p85a2/2b2/2 cells express less late protein than the
p85a2/2 cells, which express less than control cells. As a control,
neither the p85-deficient cells nor the inhibitor-treated cells showed

GFP). As shown in Figures 2A and 2B, treatment of infected cells
post-adsorption with AS1 decreased F13 and B5 accumulation as
measured by western analysis with GFP antibody. AS1 also
reduced the levels of IMV-specific protein P4b/4b by 43.6% and
30.9% after 6 hours, and by 56% and 61.4% after 16 hours
(Figure 2C). Notably, AS1 did not appear to affect the cleavage of
the core protein P4b into 4b, a proteolytic step mediated by I7
during viral maturation [68]. In contrast, AS2 did not appear to
cause significant decreases in F13, B5 or P4b levels, and did not
affect proteolysis of P4b into 4b (Figure 2C). These results
demonstrate that AS1 and AS2 appear to inhibit VV maturation

Figure 3. Late viral protein synthesis is reduced in p85-deficient cells. p85-deficient cells were infected with VV at an MOI of 5 for 16 hours
and subjected to western analysis with various antibodies. A. Cells were infected with VV strain WR expressing B5-GFP under its own promoter. Filters
were probed with GFP (top) or tubulin (bottom) antibodies. B. Cells were infected with VV strain WR expressing F13-GFP. Filters were probed with
GFP (top) or tubulin antibodies. C. Cells were infected with VV strain WR for 6 or 16 hours. Filters were probed with P4b/4b or tubulin antibodies.
Results are from two or three independent trials.
doi:10.1371/journal.pone.0010884.g003
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Figure 4. PI3K inhibitors alter the distribution of F13 and B5 in infected cells. A. BHK cells were infected with VV F13-GFP, and treated with
AS1 (50 mM) or AS2 (50 mM) post-adsoption for 16 hours. Cells were fixed and stained with phalloidin to visualize actin (red) and DAPI to visualize
DNA (blue). Approximately 600 cells were counted per condition and cells were scored positive if a FITC (GFP) signal could be detected. B. BHK cells
were infected with VV B5-GFP, and treated with PI3K inhibitors post adsoption for 16 hours, and stained as in A. Approximately 400 cells were
counted per condition. C. PI3K inhibitors alter the distribution of F13-GFP in infected cells. Cells were infected and stained as in A. Note that AS1 and
AS2 cause a reduction of punctate FITC fluorescence at the cell periphery, which represents virions, as well as a reduction in the number of actin tails.
AS1 also caused F13-GFP to localize to the cytoplasm instead of on punctate virions. D. PI3K inhibitors alter the distribution of B5-GFP in infected
cells. Cells were infected and stained as in B. Note that AS1 and AS2 had similar effects on localization of B5 and F13, namely a reduction in peripheral
punctate virions and reduced numbers of actin tails. Results are from three independent trials.
doi:10.1371/journal.pone.0010884.g004

,65% (Figure 4A and 4B). Similar effects were seen with the
p110a specific inhibitor B0304. In contrast, AS2 had no effect on
the percentage of F13-GFP and B5-GFP positive cells (Figure 4A
and 4B). In addition, AS1 or B0304 altered the subcellular
localization of F13-GFP or B5-GFP fluorescence in individual
cells (not shown and Figures 4C and 4D). Control cells typically
exhibited multiple actin tails and numerous F13-GFP or B5-GFP
positive virions in the cell periphery or on the tips of actin tails.
AS1 or B0304 caused a reduction in the number of GFP-positive
virions at the cell periphery, and a concomitant reduction in the
number of actin tails (e.g. Figures 4C and 4D). Quantitation of
actin tails from a representative experiment with AS1 on BSC40
cells is presented in Figure S2. Qualitatively, AS1 caused F13GFP fluorescence to remain in a diffuse perinuclear compartment
rather than puncta (Figure 4C), whereas B5-GFP fluorescence
remained punctate (Figure 4D). AS2 was less effective than AS1,
but also appeared to reduce both the number of F13-GFP and
B5-GFP puncta at the cell periphery, and the number of actin
tails relative to DMSO-treated cells (Figures 4C, 4D and S2).
Compared to control or AS2-treated cells, the amount of the
IMV protein L1 produced in AS1-treated cells was below the
level of detection (Figure 5A).

increased TUNEL staining, suggesting that the reduction in late
protein levels did not result from increased apoptosis (Figures S1A
and S1B). Collectively, these data suggest that PI3Ks may regulate
expression of late proteins in several ways: data with p85-deficient
cells suggests that prior effects on early protein expression may
contribute, whereas data with AS1 suggests that PI3Ks may affect a
subsequent step(s). We cannot rule out the possibility that DNA
replication may also be regulated by PI3Ks.

PI3Ks regulate localization of L1, F13 and B5
Previous studies demonstrate that F13 and B5 are required for
envelopment of IMV [69,70,71,72,73], and that F13 regulates B5
movement from the Golgi to post-Golgi vesicles [35]. Because
phosphoinositides are important regulators of endosome trafficking and Golgi structure, we hypothesized that PI3K inhibition or
absence could disrupt IMV envelopment and, consequently,
localization of B5 and F13. To test this, we assessed whether
treatment with PI3K inhibitors altered the subcellular localization
of F13, B5, and L1 in cells infected with VV F13-GFP, VV B5GFP or WR.
AS1 reduced the percentage of infected cells expressing
undetectable levels of F13-GFP by ,50% or B5-GFP by

Figure 5. PI3K inhibitors alter the levels of L1 in infected cells. A. BHK cells were infected with VV WR, and treated with AS1 (50 mM) or AS2
(50 mM) post-adsoption for 16 hours. Cells were fixed and stained with phalloidin to visualize actin (red), DAPI to visualize DNA (blue), and stained
with L1 antibodies to visualize IMV. Note that AS1 causes a reduction of punctate FITC fluorescence in the cells, as well as a reduction in the number
of actin tails. AS2 also causes a modest reduction in the number of actin tails relative to DMSO controls. Results are from two independent trials.
doi:10.1371/journal.pone.0010884.g005
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Figure 6. Localization of F13-GFP and L1 in p85-deficient cells. A. p85-deficient cells were infected with VV F13-GFP for 16 hours. Cells were
fixed and stained with phalloidin to visualize actin (red) and DAPI to visualize DNA (blue). Note that in the p85a2/2 and p85a2/2b2/2 cells there is a
reduction of punctate FITC fluorescence at the cell periphery, which represents virions, as well as a reduction in the number of actin tails. F13 remains
in a peri-nuclear location in p85-deficient cells. B. L1 production and localization in p85-deficient cells. p85-deficient cells were infected with VV,
strain WR for 16 hours. Cells were fixed and stained with phalloidin to visualize actin (red), DAPI to visualize DNA (blue), and L1 antibody, followed by
FITC conjugated anti-Mouse antibody. No difference in L1 localization the p85-deficient cells compared to wild type cells was apparent. Results are
from three independent trials.
doi:10.1371/journal.pone.0010884.g006

Another measure of released virus is the comet, an archipelago
of small plaques that are evident adjacent to the main plaque
(arrow in Figure 8E, DMSO) and have been attributed to the
release of the EEV [69,75]. Comets are particularly apparent with
the poxvirus strain IHD-J [76]. Upon infection of cells with IHD-J
and treatment with 50 mM AS2 or 20 mM B0304, plaques still
form but comets are not evident (Figure 8E and Figure S6). By
contrast, 50 mM AS1 and 20 mM LY294002 reduced the overall
plaque size but comets are still visible, albeit smaller than those
evident on control cells.

We also performed spinning disk microscopy on HeLa cells
treated with PI3K inhibitors and infected with B5-GFP to more
clearly resolve membrane localization of late proteins. As seen in zstack videos, B5-GFP fluorescence in untreated HeLa cells
localized to both the plasma membrane and to punctate structures
on the plasma membrane (Movie S1). Treatment with AS1 caused
B5-GFP to localize to a perinuclear location, albeit with some
fluorescence evident in punctate structures (Movie S2). Treatment
with AS2 had a similar effect and caused B5 to localize to vacuoles
and a small amount on the plasma membrane (Movie S3).
Compared to wild type cells, p85a2/2 and p85a2/2b2/2 cells
had fewer actin tails (Figure 6A, 6B, 7A, and 7C), and fewer B5GFP- or F13-GFP fluorescent puncta in the cellular periphery (e.g.
Figure 6A and 7A, lower panels). When evident, B5-GFP and F13GFP fluorescence localized in a perinuclear region (Figures 6A and
7A, S3, Movies S4 and S5). However, the percentage of cells
expressing detectable B5-GFP fluorescence was markedly reduced
in p85a2/2b2/2 cells (Figure 7B). No significant difference in the
amount or localization of the L1 protein was evident (Figure 6B) as
measured by cellular fluorescence. Collectively, these observations
indicate that PI3Ks mediate the localization of F13 and B5, and
levels of L1, though some differences between the inhibitors and
the p85-deficient cells were evident.

PI3K inhibitors have limited toxicity
We considered the possibility that the drugs may have
deleterious effects on cells. Therefore, we conducted toxicity
assays during the same time periods that were used for the growth
curves. Specifically, we measured the effect of the PI3K inhibitors
on cellular respiration using an MTS assay (Figure 8F) and on cell
viability using a trypan blue exclusion assay (Figure 8G). The MTS
assay was conducted on uninfected BSC-1 cells at different drug
concentrations for 8, 12, and 24 hours to calculate the amount of
drug needed to reduce formazan production by half (CC50).
Although the MTS assay indicated some cellular toxicity at high
concentrations, we found that the cells remained impermeable to
trypan blue dye (Figure 8G). Thus, although PI3K inhibitors may,
at high concentrations disrupt mitochondrial enzymes, they do not
appear to disrupt the cellular membrane. A TUNEL assay
conducted at 16 hours post drug addition confirmed that the PI3K
inhibitor treated cells and p85-deficient cells did not have
significantly increased the rates of apoptosis (Figure S1A and
S1B). Together, these data indicate that the compounds did not
have significant toxic effects at the concentrations used to inhibit
viral phenotypes and at exposure times relevant to this study.
Moreover, the presence of plaques, albeit small ones, in the
presence of drug suggests that inhibition of morphogenesis is not
complete at the concentrations tested.

PI3Ks regulate production of IMV and the amount of
released virus
Based on the immunofluorescence microscopy, we hypothesized
that PI3Ks may control formation of IMV and the wrapping of
IEV/EEV. To assess viral production and released virus, we
constructed growth curves at high and low MOI in the presence or
absence of PI3K inhibitors. For all of these experiments, inhibitors
were added one hour post adsorption to eliminate possible effects
of PI3Ks on entry. At an MOI of 0.01 (Figure 8A), AS1 decreased
the amount of cell-associated virus (CAV) relative to the DMSO
controls by 20.8-fold. These effects appear similar to those
observed with rifampicin (0.1 mg/mL), which blocks the morphogenesis of IMV and reduced viral loads by 15.4-fold (Figure 8A,
see also [74]). In addition to the inhibitory effects on CAV
production, AS1 also reduced the amount of virus released from
cells by 127.8-fold (Figure 8B). AS2 treatment moderately reduced
the production of CAV by 5-Fold (Figure 8A) and the amount of
released virus by 28.8-fold (Figure 8B). No significant difference
was evident in the amount of cell-associated and released virus
produced in the p85WT and p85a2/2 cells at an MOI of 0.01
(Figure 8C and 8D). By contrast, p85a2/2b2/2 cells produced
19.3-fold less CAV, and released 20-fold less EEV (Figure 8C and
8D). For both the PI3K inhibitor-treated and p85-deficient cells,
similar fold decreases were observed in virion production and
release at MOIs ranging from 0.0001 to 5 (Figures S4A-D and
S5A-D), suggesting that the observed effects reflected a role for
PI3Ks in morphogenesis rather than cell-to-cell spread. Moreover,
these data suggest that the block of virion morphogenesis by the
PI3K inhibitors is incomplete, and it cannot be overcome simply
by adding more virus to cells.
PLoS ONE | www.plosone.org

PI3K inhibitors regulate virion morphogenesis at two
distinct stages
To test the possibility that PI3K are directly involved in virion
morphogenesis, we next visualized viral maturation by electron
microscopy (EM) (Figure 9). Ultrastructural analysis of cells
infected with the poxviruses MVA (Figure 9A-C) and B5-GFP,
strain WR (Figure 9D-F) revealed virions at different stages of
morphogenesis, as reported [31,77]. These stages are annotated
in Figure 9A and 9D and include 1) crescents; 2) immature
virions (IV); 3) intracellular mature virions (IMV); 4) intracellular
enveloped virions (IEV)); 5) cell-associated enveloped virions
(CEV); and 6) extracellular enveloped virions (EEV). Treatment
of cells with AS1 for 16 hours post-viral entry resulted in an
apparent increase in the number of immature virions compared
to untreated cells (Figure 9B and 9E). In addition, we could find
few IMV. In contrast, AS2-treated cells had large numbers of
IMV and EEV are not evident on the plasma membrane
(Figure 9C and 9F). Additional images are presented in Figures
S7, S8, S9, S10.
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Figure 7. Localization of B5-GFP in p85-deficient cells. A. p85-deficient cells were infected with VV B5-GFP for 16 hours. Cells were fixed and
stained with phalloidin to visualize actin (red) and DAPI to visualize DNA (blue). Note that in the p85a2/2 and p85a2/2b2/2 cells there is a reduction
of punctate FITC fluorescence at the cell periphery, which represents virions, as well as a reduction in the number of actin tails. B5 remains in a perinuclear location in p85-deficient cells. B. p85-deficient cells were infected as in A and percent B5-GFP cells were quantified. Approximately 400 cells
were counted per condition and cells were scored positive if a FITC (GFP) signal could be detected. p85a2/2b2/2 cells had significantly reduced rates
of B5-GFP positive cells. Results are from three independent trials. C. p85-deficient cells form fewer actin tails than p85WT cells. Actin tails were
counted for ,10 cells per condition. Data is from one representative experiment.
doi:10.1371/journal.pone.0010884.g007

membrane of p85a2/2b2/2 cells (Figure 10A). Similar to the AS2treated cells, we also observed large numbers of IMV (Figure 10B).
Additional images are presented in Figures S11, S12, S13.
Collectively these data suggest that PI3Ks regulate morphogenesis
at two distinct transitions; IV to IMV transition (AS1-sensitive), and
IMV envelopment to form IEV (AS2-sensitive, p85-dependent).

Similar to the untreated BHK cells, the p85WT cells exhibited
virions in multiple stages of maturation (not shown). p85a2/2b2/2
cells also had virions in multiple stages of maturation. These stages
are annotated in Figure 10C and include 1) Crescents, 2) IV, and 3)
IMV. However, in contrast to the p85WT cells, we were unable to
find IEV in sections, and EEV are not evident on the plasma
PLoS ONE | www.plosone.org
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Figure 8. PI3K absence or inhibition reduces IHD-J virion production and release. A-B. Multistep growth curves of cell-associated (A) or
released virus (B) conducted at an MOI of 0.01. AS1 and AS2 were used at 50 mM, Rifampicin 0.1 mg/mL, and the carrier DMSO at 0.5%. A. Multistep
growth curves of cell-associated infectious virions, MOI of 0.01. AS1 and rifampicin reduce the amount of virus produced over time relative to DMSO
control cells, (20.8-fold and 15.4-fold reduction at 36 hours). AS2 caused a modest reduction in the amount of virus produced over time relative to
DMSO controls (5-fold reduction at 36 hours). B. Multistep growth curves of released infectious virions, MOI of 0.01. Note that AS1, AS2, and
rifampicin reduce the amount of virus released into the supernatant (Fold reduction at 36 hours: AS1- 127.8-fold, AS2- 28.8-fold, Rifampicin- 55.6fold). C-D. Multistep growth curves of cell-associated or released virus conducted at an MOI of 0.01 in p85-deficient cells. C. Multistep growth curves
of cell-associated infectious virions, MOI of 0.01. From 8 to 36 hours, a reduction in the amount of virus produced was apparent in p85a2/2b2/2 cells
compared to the p85WT and p85a2/2 cells (19.3-fold reduction at 36 hours). D. Multistep growth curves of released infectious virions, MOI of 0.01. A
reduction in the amount of virus released from the p85a2/2b2/2 cells compared to the p85WT and p85a2/2 cells was apparent (20-fold reduction at
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36 hours). Results are from one trial conducted in triplicate, and match growth curves conducted using WR. E. PI3K inhibitors reduce comet tails
formed by VV, strain IHD-J. Monolayers were infected with 100PFU of virus, and plaques were visualized 48 hours later with crystal violet stain.
Experiments were conducted in three independent trials. F,G. Toxicity assays of PI3K inhibitors on uninfected cells. F. MTS assay on BSC-1 cells
treated with PI3K inhibitors for different periods of time. MTS production is a measure of mitochondrial metabolism. Values represent the
concentration of drug (in mM) required to reduce formazan production by half. Experiments were conducted in two independent trials. G. Trypan
blue exclusion assays of BHK cells treated with PI3K inhibitors (AS1 and AS2, 50 mM) for different time periods.
doi:10.1371/journal.pone.0010884.g008

pretreatment with LY294002 and infection with Cowpox, but
not VV [48]. Because both Hu et al. and Soares et al. pretreated
cells with LY294002, it is possible that the observed defects in early
protein synthesis do not result from effects on early protein
synthesis, but rather result from defects in virion entry, a result
reported by Mercer et al. [54]. By adding our compounds post viral
adsorption we avoided such artifacts, and showed that early
protein levels are reduced in a p85-dependent, but AS1/AS2independent manner. However, we cannot rule out the possibility
that adding of AS1 or AS2 at one hour following adsorption and
entry was too late to affect a p85-dependent PI3K step that
regulates early protein expression.
Although Assarsson et al. demonstrated that E3 is expressed
early during an infection, no data exists describing the location of
E3 transcription inside or outside the virion [79]. Because VV
carries the entire complement of enzymes required for early gene
transcription within the viral core, and early protein translation
occurs after core uncoating, we hypothesize that p85-dependent
PI3Ks may function in some aspect of core uncoating
[80,81,82,83]. Therefore, if viral uncoating is delayed, E3
transcription/translation may be delayed as well. Alternatively,
Mallardo et al. have demonstrated that the sites of early protein
synthesis are distinct from the sites of DNA replication [84].
Therefore, p85-dependent PI3Ks may also function to localize the
early protein synthesis machinery.

PI3K usage by vaccinia virus is functionally redundant
The observation that p85a2/2b2/2 cells exhibited only a slight
reduction in virion production relative to wild-type cells (Figure 1B)
suggests that VV may utilize multiple PI3K in a redundant
fashion. To test this hypothesis, we assessed plaque formation in
wild type and p85a2/2b2/2 cells in the presence or absence of
PI3K inhibitors. In the p85a2/2 and p85a2/2b2/2 cells a
significant fraction of type 1 PI3K activity is reduced [50,66],
however, the type 1b, type 2 and type 3 PI3Ks are still functional.
We reasoned that a lower concentration of inhibitor would be
required to block plaque formation in knockout cells compared to
wild type cells. As shown in Figure 11A, the IC50 values, calculated
on the basis of percent reduction in plaque number, were
significantly higher for AS1 in p85WT cells (50.3 mM) compared
to p85a2/2b2/2 cells (11.2 mM). A similar result was obtained for
AS2 (37.1 mM) in p85WT cells compared to the p85a2/2b2/2
cells (21.1 mM). Together these data suggest that several PI-3
kinase isoforms, likely acting in a redundant fashion, regulate VV
morphogenesis at multiple steps.

Discussion
Herein we define the involvement of PI3Ks in orthopoxvirus
morphogenesis using PI3K inhibitors and cell lines deficient in the
regulatory subunit of Type I PI3Ks, p85. The inhibitors AS1 and
AS2 were originally developed to inhibit the p110-gamma subunit
of the Type Ib PI3K, but they also inhibit the other PI3K subtypes
at higher concentrations [61], preventing assignation of a specific
PI3K isoform to stages of orthopoxviral morphogenesis. Nevertheless, data with cell lines lacking p85 indicates that the PI3K
inhibitors are likely targeting a host kinase and not a viral one. The
inhibitors tested decrease plaque size for VV, ectromelia virus and
monkeypox virus, implying that PI3K-dependent mechanisms are
conserved among poxviruses. We hypothesize that differences in
the IC50 and IC20 values for these viruses may be due to
differential PI3K usage by the viruses, a topic that we are currently
exploring. A summary of our results using the PI3K inhibitors and
p85-deficient cells is presented in Figure 11B.

PI3K contribute to late protein expression
The observed defects in early protein levels in the p85-deficient
cells have raised the possibility that delays in late protein synthesis
can be ascribed to upstream effects on early proteins. Moreover,
we cannot rule out the possibility that DNA replication may be
delayed or diminished in these cells. However, P4b was still
proteolytically processed, implying that the I7 protease was
functional in these cells. We also found that AS1, but not AS2,
appeared to reduce late proteins F13, B5, and P4b/4b to a similar
extent as in the p85-deficient cells (Figure 11B, #3). Notably, AS1
and p85-deficient cells did not appear to exert a complete block of
morphogenesis as P4b was still proteolytically processed and
infectious virus was still produced and released in these cells.
Nevertheless, inhibitors AS1 and AS2 both reduce plaque size to a
similar degree, and our results suggest that they may be doing so
by different mechanisms.
Both inhibitors were developed to inhibit the p110-gamma
isoform of the PI3Ks and structurally, they have the same
chemical backbone, but differ in side group substitutions.
Interestingly, Camps et al. demonstrate that AS1 and AS2 inhibit
the similar classes of PI3K isoforms, albeit with different efficacy
[61]. We hypothesize that the differences in drug structure and
kinase specificity lead to the observed differences in late protein
synthesis. We cannot rule out the possibility that differences
between the p85-deficient cells and PI3K-inhibitor treated cells
may be attributed to p85-dependent, catalytic subunit–independent signaling, a mechanism that has been described previously
[50,85].
Zaborowska and Soares et al. also found that pretreatment of
VV infected cells with LY294002 reduces late IMV protein

PI3K contribution to early protein expression
We found that the PI3K inhibitors AS1 and AS2 when added
post adsorption did not affect levels of early protein E3 (Figure 1C),
whereas E3 levels were decreased in the p85 deficient cells
independent of entry (Figure 1D and 1E, Figure 11B #2). Without
EM, we cannot rule out the possibility that p85 deficient cells also
have an entry defect. However, this seems unlikely because such
an effect is not recapitulated in our growth curves (Fig. 8C and 8D,
Figure S5). Thus our data suggest that PI3Ks that depend on p85
regulate levels of early proteins, but not virion entry. The
reduction in early protein levels in the p85-deficient cells is in
agreement with those obtained by Hu et al., demonstrating that
early protein F4 levels are reduced with VV and Canarypox,
following pretreatment with PI3K inhibitor LY294002 and in cells
transiently transfected with a p85 dominant negative construct
[78]. Work by Soares et al. is in partial agreement with this result;
they observed a decrease in CrmA/SPI-2 levels following
PLoS ONE | www.plosone.org
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Figure 9. PI3K inhibitors disrupt vaccinia virus maturation. A. BHK cells were infected with MVA for 17 hours plus or minus PI3K inhibitors.
Untreated samples exhibit characteristic virion morphogenesis (4100x, Glut/KMnO4 fixative). A9:1) Crescents; 2) Immature virions; 3) Mature virion,
IMV; A0: 4) IEV; 5) CEV; 6) EEV. B. In cells treated with 50 mM AS1, virions at the immature to IMV transition, but not at later stages, are evident
(10,000x, Glut/OsO4 fixative). a) Replication center and crescents; b) Immature virion; c) Immature virion with nucleoid. C. In cells treated with 50 mM
AS2, virions at the IMV wrapping step but not at later stages are evident (6800x, Glut/KMnO4 Fix). a’) Immature virion; b’) IMV. Note the lack of virions
associated with the plasma membrane, characteristic of IEV inhibition. D. HeLa cells were infected with B5-GFP WR for 17 hours plus or minus PI3K
inhibitors. Untreated samples exhibit characteristic virion morphogenesis (10,000x, Glut/KMnO4 Fix). D’: 1) Crescents; 2) Immature virions; D0: 3)
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Mature virion, IMV; 4) IEV. E. In cells treated with 50 mM AS1, virions at the immature to IMV transition, but not at later stages, are evident (10,000x,
Glut/OsO4 Fix). a) Viral crescents; b) Immature virion; c) Immature virion with nucleoid. F. Samples treated with 50 mM AS2 are stuck at the IMV
wrapping step (7000x, Glut/KMn4). a9) Crescents; b9) Immature virion; c9) IMV. Note the lack of virions associated with the plasma membrane, a
characteristic of IEV inhibition.
doi:10.1371/journal.pone.0010884.g009

G4, phosphoprotein A13 and LY294002 pretreatment
[20,22,26,28,48]. In contrast, AS2-treated cells had large numbers
of IMV (Figure 9C and 9F), reminiscent of morphological defects
seen following IMCBH treatment [88,89]. Similar to AS2-treated
cells, p85 deficient cells did not wrap IMV to form IEV and viral
morphogenesis in these cells appears similar to the AS2-treated
cells. Furthermore, we observed similar morphological defects
following PI3K inhibition/absence in both MVA and WR infected
cells, suggesting that the involvement of host PI3K is conserved
across multiple poxviral species. Overall, the similarity of viral
morphological blocks seen in inhibitor treated cells and the p85deficient cells demonstrates that PI3Ks function to correctly
localize envelope-specific viral proteins to nascent envelopes,
leading to the formation of the envelope membranes.

production, a result consistent with our AS1 data [48,67].
Zaborowska et al. demonstrate that this decrease is due to
disrupted eIF4F complex following PI3K inhibition [67]. Furthermore, Hu et al. identified as similar reduction in late protein F4
mRNA levels following LY294002 pretreatment or in cells
expressing a p85 dominant negative construct [78]. Our results
with PI3K inhibitors and in p85 deficient cells are consistent with,
but also expand and qualify these results. We demonstrate that
AS1 not only reduces late IMV proteins, but also reduces late
IEV/CEV/EEV-specific proteins as well (Figure 2). Furthermore,
our data provides a context for the involvement of host PI3K in
VV morphogenesis by tying these results to specific p85 isoforms.

PI3K regulate B5 and F13 trafficking
Husain et al. demonstrated that F13 regulates B5 movement
from the Golgi to post-Golgi vesicles [35]. Specifically, upon
expression of F13 with mutations in the palmitylation site or with
mutations in the phospholipase active site motif, both B5 and F13
remain in the cytoplasm or cis-Golgi (p115-positive) structures [35]
and fail to localize to peripheral punctate structures. Roper and
Sung further demonstrate that these same mutations in the
phospholipase C motif reduce both plaque and IEV/CEV/EEV
formation [72,73]. Furthermore, butanol-1 treatment, which
inhibits phospholipase D activity, also decreases EEV production
and redistributes F13 to the juxtanuclear Golgi region [86].
Moreover, Ward et al. also showed that mutations in a dileucine
motif of a chimeric B5 protein could prevent plasma membrane
retrieval, as measured by antibody uptake and staining, implying a
mechanism for B5 retrograde trafficking [87]. Altogether, these
results demonstrate that F13 and B5 localization depends on
endosomal trafficking, and given the potential phospholipase
activity of F13, may also depend on phospholipid turnover.
Consistent with this idea, we found that localization of F13 and
B5 was dependent on PI3K activity. AS1 treatment caused F13 to
localize to a cytoplasmic compartment, in a manner reminiscent of
F13(C186S) palmitylation and F13(D319E) phospholipase D
(PLD) active site mutants, which exhibited similar localization
[35]. In contrast, AS2 treatment caused B5 and F13 to remain in a
perinuclear compartment, although ‘‘breakthrough’’ wrapped
virus and actin tails were observed. The phenotype seen in the
p85-deficient cells appears to be closer to that seen with AS2
treatment and resembles the F13(C185S) and F13(K314R)
mutants, which remain in a cis-Golgi (p115-positive) compartment
[35]. The phenotypic similarities of PI3K absence/inhibition with
the palmitylation and PLD active site mutants demonstrates that
F13 and B5 trafficking is dependent on membrane association and
lipid signaling.

VV Uses PI3K in a redundant manner
Several observations suggest that VV uses PI3K redundantly.
We define redundancy as the capacity to use PI3K at multiple
steps of virion morphogenesis and the ability to use multiple PI3K
at each morphological step. In contrast to previous reports with
particular PI3K inhibitors (e.g. LY294002 and Wortmannin), our
use of several PI3K inhibitors has allowed us to resolve several
stages at which PI3K act, including the IV to IMV transition and,
the IMV to IEV transition. Furthermore, we observed that the
p85a2/2b2/2 cells had delayed early protein synthesis and were
deficient in IMV wrapping. These data suggest that p85dependent PI3K and PI3K-inhibitor sensitive PI3K are used for
multiple steps of virion morphogenesis.
Furthermore, we find that VV can use multiple PI3K at each
morphological step, because plaque formation was only reduced
by half in the p85a2/2b2/2 cells compared to the p85a2/2 and
p85WT cells (Figure 1B). This incomplete phenotype lead us to
hypothesize that PI3K activity persisted in the p85-deficient cells
because the p85 regulatory subunit is only used by the type 1a
PI3K kinases, and the type 1b, type 2 and type 3 phosphatidylinositol 3-kinases are still functional in the p85a2/2b2/2 cells.
We found that addition of the PI3K inhibitors had an additive
effect in reducing the number of plaques on the p85 deficient cells
and could completely eliminate plaques at higher concentrations.
Together, these observations suggest that VV uses PI3K in a
functionally redundant manner; that is, VV uses multiple PI3Ks at
each of several steps in morphogenesis. Our use of PI3K inhibitors
in conjunction with p85-deficient cells provides a significant
advance in our understanding of how PI3Ks are utilized by
poxviruses.
PI3K redundancy may help to extend both the host range and
cell type specificity for the virus, as PI3K isoforms are differentially
expressed through out the body [37]. Such redundancy is not
without precedent. Viable mice can be generated from mice
missing one splice variant of p85a, but not from mice missing all
p85a splice variants, implying that the p85a isoforms are
functionally redundant [90]. Moreover, redundancy may also be
a common feature of host-pathogen signaling. Swimm et al. and
Reeves et al. demonstrate that EPEC and VV can use host tyrosine
kinases redundantly to make actin protrusions [52,91,92].
Redundancy in PI3K signaling has also been reported for Ebola
entry into p85-deficient cells [93], and insulin signaling in HepG2
cells [94].

PI3K mediate VV morphogenesis
Our data with PI3K inhibitors and p85-deficient cells suggest
that morphogenesis is differentially regulated by multiple PI3Ks at
different stages. Specifically, differences in virion production for
both the PI3K inhibitors and the p85-deficient cells were evident
in growth curves, by microscopy, and by electron microscopy, and
indicate that PI3Ks regulate production of both IMVs (Figure 11B,
#5) and IEV/EEVs (Figure 11B, #7). The AS1 inhibitor
morphological block appeared reminiscent of morphological
defects seen with the vaccinia redox proteins, A2.5, E10,
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Figure 10. VV morphogenesis is disrupted in the p85-deficient cells. p85a2/2b2/2 cells were infected with B5-GFP WR for 17 hours. A,B,C.
p85a2/2b2/2 cells exhibit characteristic virion morphogenesis (A,B. 4,100X, OsO4 Fix; C. 14,000X OsO4 fix), but are stuck at the IMV wrapping step. 1)
Crescents; 2) Immature virions; 3) Mature virion, IMV (4,100X, OsO4 Fix). Note the lack of virus associated with the plasma membrane.
doi:10.1371/journal.pone.0010884.g010

of both the protein components (e.g. B5 and F13) as well as lipid
components, as the IMV form has been shown to be enriched in
phosphoinositides [7,101,102]. PI3K interact with many of the rab
proteins [103,104], and rab1 and rab2 are markers for the
intermediate compartment [105] and have already been shown to
co-localize with VV replication centers [7,106], perhaps suggesting
a mechanism for PI3K-dependent acquisition of the IMV
envelope acquisition.
PI3K may also regulate IMV wrapping to form IEV. Chen et al.
provide evidence that F13 can interact with host proteins TIP47
and rab9 to nucleate the IMV wrapping complex [107].
Membranes derived from early endosomes can also envelope
IMV particles, as Tooze et al. demonstrate that cells treated with

Why would VV use PI3Ks for virion morphogenesis?
Other viruses, including VV and cowpox, activate PI3K to
inhibit cellular apoptosis [47,48,49]. However, other pathogens,
like Salmonella and M. tuberculosis, disrupt PI3K signaling to inhibit
endosome to lysosome fusion, thereby creating a novel pathogenspecific endosome [95,96,97]. PI3K signaling has been shown to
act as a signaling molecule, creating phosphatidylinositol 3phosphate (PI3P) microdomains on membranes [98]. The local
PI3P concentration on endosomes can act as a ‘‘zipcode’’ within
the host cells; for instance, PI3P is usually localized to multivesicular bodies, autophagosomes and early endosomes [99,100].
We demonstrate that VV uses PI3Ks to correctly target and
localize components required for morphogenesis. This may consist

Figure 11. PI3K usage by VV is functionally redundant. A. PI3K inhibitors reduce plaque numbers in p85-deficient cells. Drugs were added to
p85-deficient cells post viral adsorption at different concentrations. The concentration of drug needed to reduce plaque numbers by half (IC50) was
calculated by fitting the data to a linear regression model using Prism software (GraphPad Prism Software, Inc., La Jolla, CA). IC50 values are lower for
p85-deficient cells. Results are from three independent trials. B. Summary of vaccinia virus morphogenesis in p85-deficient cells or following PI3K
inhibitor treatment. After VV entry (1) virion uncoating and early protein synthesis occurs (2). These steps are followed by late protein production (3),
formation of viral replication centers and viral crescents (4). Crescents envelope viroplasm to form immature virions (IV, 5). The cores of IV condense
to form mature virions (IMV, 6). A subset of the IMV traffic to the Golgi Complex where they are enveloped in a host cell derived membrane to form
IEV (7). IEV fuse with the plasma membrane, releasing virus to the extracellular milieu, (CEV, 8). CEV form actin tails beneath the virus and ultimately,
release to form extracellular enveloped virions (EEV, 9). Our results suggest that involvement of PI3Ks at steps 2,3,5, and 7. Steps 2 and 7 are disrupted
in the p85-deficient cells, AS1 treatment disrupts steps 3 and 5, and AS2 disrupts steps 7. Thus, PI3K usage by VV is redundant; multiple PI3Ks acting
at each of several steps regulate VV morphogenesis.
doi:10.1371/journal.pone.0010884.g011
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and fresh media was added. C-D. Multistep growth curves
conducted in p85-deficient cells. Cells were infected at different
MOIs with VV strain IHD-J as in A and B.
Found at: doi:10.1371/journal.pone.0010884.s006 (0.63 MB TIF)

Brefeldin A still envelope IMV, and that these IEV are positive for
exogenously added HRP [30]. Mechanistically, PI3K inhibitors or
deficient cells could disrupt IMV wrapping by interfering with
Golgi and/or early endosome trafficking. Since other enveloped
viruses need to acquire a lipid membrane, it is possible that PI3Ks
and lipid dynamics may be utilized by other wrapped viruses to
highjack host cell membranes. Overall, the small molecules that
target PI3Ks or other host enzymes that regulate morphogenesis
yield new insight into the mechanism of viral envelopment and
may represent a new class of antiviral therapeutic drugs, a prospect
that we are currently testing.

Figure S6 PI3K inhibitors reduce comet tails formed by VV,
strain IHD-J. Insets show enlarged image of plaques boxed in top
panels. Insets are at the same scale.
Found at: doi:10.1371/journal.pone.0010884.s007 (2.20 MB TIF)
Figure S7 PI3K inhibitors disrupt vaccinia virus maturation.
BHK cells were infected with MVA for 17 hours and treated with
50 mM AS1 (8,200X, KMnO4 fix).
Found at: doi:10.1371/journal.pone.0010884.s008 (9.91 MB
PSD)

Supporting Information
Table S1 20% inhibitory concentration (IC20) of PI3K inhibitors
added post-adsorption to poxvirus-infected monolayers. 1[63]
2[113] 3[67]
Found at: doi:10.1371/journal.pone.0010884.s001 (0.03 MB
DOC)

Figure S8 PI3K inhibitors disrupt vaccinia virus maturation.
BHK cells were infected with MVA for 17 hours and treated with
50 mM AS1 (8,200X OsO4 Fix).
Found at: doi:10.1371/journal.pone.0010884.s009 (9.59 MB
PSD)

Figure S1 S1A. TUNEL assay for PI3K inhibitor treated BHK
cells. PI3K inhibitors were added to uninfected BHK cells on glass
coverslips for 16 hours. Media was removed and the cells were
fixed and processed for the TUNEL assay. AS1 and AS2 were
added at 50 mM and were in 0.5% DMSO. B0304 and LY294002
were at 20 mM and were in 0.2% DMSO. DNase1 was used as a
positive control. Approximately 700 cells were counted per
condition. PI3K inhibitors did not increase the levels of apoptosis
in the BHK cells following 16 hour treatment. S1B. TUNEL assay
for p85-deficient cells. Uninfected p85WT or -deficient cells were
added to glass coverslips for 16 hours, and then fixed and
processed for the TUNEL assay. DNase1 was used as a positive
control. Approximately 700 cells were counted per condition. The
rates of apoptosis are not increased in the p85-deficient cells.
Found at: doi:10.1371/journal.pone.0010884.s002 (0.23 MB TIF)

Figure S9 PI3K inhibitors disrupt vaccinia virus maturation.
HeLa cells were infected with B5-GFP for 17 hours and treated
with 50 mM AS2 (8,200X, KMnO4 fix).
Found at: doi:10.1371/journal.pone.0010884.s010 (5.22 MB TIF)
Figure S10 PI3K inhibitors disrupt vaccinia virus maturation.
HeLa cells were infected with B5-GFP for 17 hours and treated
with 50 mM AS2 (8,200X, KMnO4 fix).
Found at: doi:10.1371/journal.pone.0010884.s011 (5.30 MB TIF)
Figure S11 VV morphogenesis is disrupted in the p85-deficient
cells. p85a2/2b2/2 cells were infected with B5-GFP WR for
17 hours (2,700X, OsO4 Fix).
Found at: doi:10.1371/journal.pone.0010884.s012 (3.45 MB TIF)
Figure S12 VV morphogenesis is disrupted in the p85-deficient
cells. p85aa2/2 b2/2 cells were infected with B5-GFP WR for
17 hours (4,100X, OsO4 fix).
Found at: doi:10.1371/journal.pone.0010884.s013 (5.47 MB TIF)

Figure S2 PI3K inhibitors reduce the number of actin tails/cell.
BSC40 cells were infected with WR and treated with 100 mM AS1

and AS2 post-adsorption, and the cells were fixed and stained with
FITC-phalloidin 16 hours later. The number of actin tails was
counted on ten cells per condition.
Found at: doi:10.1371/journal.pone.0010884.s003 (0.75 MB TIF)

Figure S13 VV morphogenesis is disrupted in the p85-deficient
cells. p85a2/2b2/2 cells were infected with B5-GFP WR for
17 hours. (8,200X OsO4 fix).
Found at: doi:10.1371/journal.pone.0010884.s014 (5.07 MB TIF)

Figure S3 Screen shots from z-stack of spinning disk microscopy
of p85WT or p85a2/2b2/2 cells infected with F13-GFP. Note the
punctate virions in the p85WT cells, and the lack of these
structures in the p85a2/2b2/2 cells. Instead, the F13 protein
localizes to a peri-nuclear structure.
Found at: doi:10.1371/journal.pone.0010884.s004 (1.09 MB TIF)

Movie S1 Spinning disk microscopy of untreated HeLa cells
infected with VV B5-GFP strain WR for 17 hours.
Found at: doi:10.1371/journal.pone.0010884.s015 (2.55 MB
MOV)
Movie S2 Spinning disk microscopy of HeLa cells infected with
VV B5-GFP strain WR and treated with AS1 50 mM for 17 hours.
Found at: doi:10.1371/journal.pone.0010884.s016 (1.68 MB
MOV)

A-B. Single step growth curves conducted at MOI = 5
in PI3K inhibitor-treated cells. VV, strain IHD-J, was allowed to
bind and enter BHK cells for 1 hour, monolayers were washed
with PBS twice, and media was added containing PI3K inhibitors
(50 mM), DMSO (0.5%) or Rifampicin (0.1 mg/mL). C-D.
Multistep growth curves conducted in PI3K inhibitor-treated
cells. Cells were infected at different MOIs with Vaccinia virus,
strain IHD-J. Virus was allowed to bind and enter BHK cells for 1
hour, monolayers were washed with PBS twice, and media was
added containing PI3K inhibitors (50 mM), DMSO (0.5%) or
Rifampicin (0.1 mg/mL). Supernatants and monolayers were
collected at 24 hours post infection.
Found at: doi:10.1371/journal.pone.0010884.s005 (0.68 MB TIF)
Figure S4

Movie S3 Spinning disk microscopy of HeLa cells infected with
VV B5-GFP strain WR and treated with AS2 50 mM for 17 hours.
Found at: doi:10.1371/journal.pone.0010884.s017 (2.26 MB
MOV)
Movie S4 Spinning disk microscopy of p85WT cells infected
with VV F13-GFP for 17 hours.
Found at: doi:10.1371/journal.pone.0010884.s018 (7.92 MB
MOV)
Movie S5 Spinning disk microscopy of p85a2/2b2/2 cells

infected with VV F13-GFP for 17 hours.
Found at: doi:10.1371/journal.pone.0010884.s019 (13.68 MB
MOV)

A-B. Single step growth curves conducted at MOI = 5
in p85-deficient cells. VV strain IHD-J was allowed to bind and
enter cells for 1 hour, monolayers were washed with PBS twice,

Figure S5
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